Rchr
J-GLOBAL ID:201801002832956822   Update date: Sep. 11, 2024

Ohki Kentaro

オオキ ケンタロウ | Ohki Kentaro
Affiliation and department:
Research field  (1): Fetal medicine/Pediatrics
Research theme for competitive and other funds  (11):
  • 2021 - 2025 Analyis of molecular characteristics of refractory/relapsed lymphoblastic lymphoma of children and young adult.
  • 2018 - 2021 The elucidation of the genetic abnormalities of leukemia/lymphoma indicating characteristic cell marker and the establishment of new disease entity
  • 2014 - 2017 The study of the prognostic factor search in pediatric acute myeloid leukemia using the next generation sequencing and MLPA method
  • 2014 - 2017 Next generation sequencing analysis of transient abnormal myelopoiesis and acute megakaryoblastic leukemia in Down syndrome
  • 2013 - 2016 Clonal evolution analyses between relapse and diagnosis samples in pediatric acute myeloid leukemia by next generation sequencer
Show all
Papers (131):
  • Shota Kato, Shin-Ichi Tsujimoto, Jun Matsubayashi, Shotaro Iwamoto, Hidefumi Hiramatsu, Yusuke Okuno, Tatsuya Kamitori, Kentaro Ohki, Takao Deguchi, Nobutaka Kiyokawa, et al. Adverse prognostic impact of <i>KIT</i> exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with <i>RUNX1::RUNX1T1</i>. Haematologica. 2024
  • Masahiro Yoshitomi, Shin-Ichi Tsujimoto, Junji Ikeda, Tomoko Kawai, Kentaro Ohki, Yusuke Hara, Genki Yamato, Reo Tanoshima, Daisuke Tomizawa, Akira Shimada, et al. High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Pediatric blood & cancer. 2024. e31151
  • Masahiro Sekimizu, Fukano R, Koga Y, Mitsui T, Fujita N, Mori T, Hori D, Tanaka M, Ohki K, Iwafuchi H, et al. Rituximab-combined Anthracycline-free Chemotherapy in Newly Diagnosed Paediatric and Adolescent Patients with Non-high-risk Aggressive Mature B Cell Lymphoma: Protocol for a Single-arm, Open-label, Multicentre, Phase II Study (The Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20). BMJ Open. 2024
  • Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, et al. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial. European journal of haematology. 2023
  • Mayumi Hangai, Takahisa Kawaguchi, Masatoshi Takagi, Keitaro Matsuo, Soyoung Jeon, Charleston W K Chiang, Andrew T Dewan, Adam J De Smith, Toshihiko Imamura, Yasuhiro Okamoto, et al. Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients. Haematologica. 2023
more...
MISC (142):
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page